Regulatory News & FDA Approvals

In Brief This Week: Seagen, Ideaya Biosciences, Cellistic, AstraZeneca, Kinnate Biopharma

Eli Lilly's Retevmo Nabs Tumor-Agnostic Approval From FDA in Cancers With RET Gene Fusions

Immunitas Cleared by FDA to Begin Trial of IMT-009 in Hematologic Malignancies, Solid Tumors

Verismo Therapeutics to Begin Phase I Trial of Autologous Cell Therapy SynKIR-110

EMA's CHMP Recommends Gilead's Yescarta for Second-Line Lymphoma

BMS Combo Immunotherapy Opdualag Approved in Europe for Biomarker-Defined Melanoma Patients

NICE Finds Lynparza Not Cost-Effective in BRCA1/2-Mutated Advanced Prostate Cancer

UK's MHRA Approves Adjuvant Lynparza for BRCA-Mutant, High-Risk Early Breast Cancer

Owkin Digital Pathology Algorithms for Colorectal, Breast Cancer Receive CE Mark

Aston Sci. to Launch Phase II US Study of Experimental Vaccine in HER2-Low Breast Cancer Patients

Amgen's Lumakras Bests Chemo, Meets Primary Endpoint in CodeBreak 200 Trial

Novartis' Scemblix Nets European Approval for Subset of CML Patients

Incyte's Pemazyre Nets FDA Approval for Rare Blood Cancer

In Brief This Week: Immatics, Aktis Oncology, Daiichi Sankyo, Roche Pharma India, Genetron

AstraZeneca's Tagrisso, Lynparza Net Adjuvant Approvals in Japan

Oncgnostics Epigenetic Cervical Cancer Test Wins Chinese Regulatory Approval

K36 Therapeutics Gets FDA Clearance to Start Phase I Trial of Multiple Myeloma Candidate

In Brief This Week: Genprex, Strata Oncology, Bristol Myers Squibb, Turning Point Therapeutics